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ABSTRACT
Double-stranded sections of mRNA are often invit-
ing sites of interaction for a wide variety of proteins
and small molecules. Interactions at these sites can
serve to regulate, or disrupt, the homeostasis of the
encoded protein products. Such ligand target sites
exist as hairpin–loop structures in the mRNAs of
several of the proteins involved in iron homeostasis,
including ferritin heavy and light chains, and are
known as iron responsive elements (IREs). These
IREs serve as the main control mechanism for iron
metabolism in the cell via their interaction with the
iron regulatory proteins (IRPs). Disruption of the
IRE/IRP interaction could greatly affect iron meta-
bolism. Here, we report that anthracyclines, a
class of clinically useful chemotherapeutic drugs
that includes doxorubicin and daunorubicin, specif-
ically interact with the IREs of ferritin heavy and
light chains. We characterized this interaction
through UV melting, fluorescence quenching and
drug–RNA footprinting. Results from footprinting
experiments with wild-type and mutant IREs indi-
cate that anthracyclines preferentially bind within
the UG wobble pairs flanking an asymmetrically
bulged C-residue, a conserved base that is essential
for IRE–IRP interaction. Additionally, drug–RNA
affinities (apparent Kds) in the high nanomolar
range were calculated from fluorescence quenching
experiments, while UV melting studies revealed
shifts in melting temperature ("Tm) as large as
108C. This anthracycline–IRE interaction may contri-
bute to the aberration of intracellular iron homeo-
stasis that results from anthracycline exposure.
The unique tertiary structures attainable by RNA, and the
burgeoning knowledge of the ligand speciﬁcity of those
tertiary structures, have revealed RNA to be an inviting
target for a variety of proteins and small molecules (1–7).
The interaction of these ligands with mRNA can alter the
translation of the encoded protein. The iron responsive
elements (IREs) of proteins involved in iron metabolism
serve as the premier regulatory site of translation due to
their unique tertiary structure. IREs are  30-nt long hair-
pin–loop structures in the untranslated regions (UTRs) of
several iron metabolism proteins including both ferritin
subunits (Figure 1), ferroportin and the erythroid isoform
of aminolevulinate synthase, eALAS (8,9) The structure
and sequence of IREs is highly conserved throughout all
of the animal kingdom including early metazoan (10). The
homeostasis of IRE containing proteins is regulated by the
iron-dependent availability of the IRP proteins (8). Ligand
interaction in the UTRs of mRNA can serve to stabilize or
destabilize the mRNA, and thus increase or decrease trans-
lation. In general, binding of a protein or small molecule in
the 50-UTR inhibits translation by deterring the associa-
tion of translation factors and preventing the assembly of
the ribosome. Conversely, the binding of a ligand in the
30-UTR upregulates translation by protecting against
nuclease degradation (8). In the case of IRE–IRP interac-
tion, at low intracellular iron concentrations, IRP1 is con-
verted into its active binding state through the dissociation
of its 4Fe-4S cluster. This active state then binds to the 50
IRE of ferritin heavy and light chain mRNAs, serving to
downregulate translation and reduce the iron-storage
capacity of ferritin (8). Disruption of this IRE/IRP inter-
action could greatly aﬀect intracellular iron handling.
Anthracyclines are powerful antineoplastic agents that
are widely used for the treatment of leukemia, lymphoma,
solid tumors and Hodgkin’s disease (11). However, the
clinical use of anthracyclines is limited by the occurrence
of both chronic and acute cardiotoxicity that can often
lead to cardiomyopathy, myocardial infarction and con-
gestive heart failure (11–13). The mitigation of these
often fatal side aﬀects is of high interest and many attempts
have been made to characterize the mechanism of anthra-
cycline cardiotoxicity. However, there is much disagree-
ment on this point in the literature. Theories include the
suppression of transcription factors, production of reactive
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decreased levels of intercardiac protective proteins and
impaired intracellular iron handling and homeostasis
(14–22). Elegant attempts have been made to tie all of
the popular pathways listed above into a single complex
model for anthracycline cardiotoxicity (23). However, the
exact method by which anthracyclines lead to cardiomyo-
pathy must still be elucidated in order to rationally design
new therapeutic options for the successful treatment of
cancer with anthracyclines.
The antitumor aﬀects of anthracyclines are attributed to
the ability of the molecules to inhibit topoisomerase by
intercalating DNA, and the speciﬁcs of this interaction
are very well-characterized (24–32). However, the ability
of these drugs to intercalate double-stranded RNA has
largely been neglected in the literature. It has previously
been observed that anthracyclines cause an imbalance in
the regulation of IRP and its binding to IREs, but it has
yet to be investigated whether this perturbation is a direct
result of anthracyclines interacting with the IREs (17,18).
Toward unraveling the mechanism of anthracycline-
induced disruption of IRE binding to IRP we investigated
the possibility of a direct interaction between anthracy-
clines and IREs harbored at the 50-UTR of ferritin
heavy and light chain mRNAs. A direct interaction of a
small molecule, such as an anthracycline, with the IRE
could change the tertiary structure of the RNA drastically
and alter the eﬀectiveness of the IRE/IRP interaction. In
this study, we characterized the isolated IREs of ferritin
heavy and light subunit mRNAs in the absence and pres-
ence of doxorubicin (DOX) and daunorubicin (DAU),
two widely used anthracyclines, via biophysical techniques
including UV melting, ﬂuorescence quenching and drug–
RNA footprinting. Results from these experiments sug-
gest that anthracyclines do indeed interact with the IRE
hairpin–loop structures in a strong and speciﬁc manner.
This interaction may contribute to the intracellular aber-
ration of iron regulatory protein homeostasis upon
anthracycline exposure.
EXPERIMENTAL PROCEDURES
Drugsand reagents
Doxorubicin hydrochloride and daunorubicin hydrochlor-
ide were procured from Oakwood Products Incorporated.
All reagents were of molecular biology grade (Sigma, St.
Louis, MO). Tubes and tips were sterile and autoclaved
prior to use. Water was ultra pure, autoclaved for 1h, and
ﬁltered through a 0.2mm ﬁlter prior to use. All buﬀers
used were also ﬁltered prior to use.
mRNA sequence selection and preparation
The mRNA sequences of the human proteins of interest
were retrieved from the Entrez Nucleotide Database
(www.pubmed.org). The UTRs of these mRNA sequences
were identiﬁed, and the folding of these sequences was
modeled in the RNAstructure Version 4.3 program
(rna.urmc.rochester.edu/rnastructure.html). The resulting
secondary structures were surveyed to identify hairpin
loop structures. The isolated sequence of the loop and
stem region of these structures, on average 30nt in
length, was then folded via the RNAstructure program
once again to ensure that the secondary structure was
maintained in the absence of the rest of the sequence
(Figure 1). The mRNA sequences of these structures
were purchased from Dharmacon Research Inc.,
Lafayette, CO, deprotected according to the manufac-
turer’s protocol, and their purity was veriﬁed via denatur-
ing urea polyacrylamide gel electrophoresis. RNA
concentrations were determined by UV-vis spectroscopy
in 1cm path length quartz cuvettes using the molar extinc-
tion coeﬃcients provided by Dharmacon.
UV-vis melting and absorption experiments
UV melting experiments were performed in the absence of
drug and in the presence of DOX or DAU at ﬁnal drug
concentrations of 5 mM and 20 mM. RNA and drug com-
plexes were formed by the addition of an aliquot of stock
drug solution in DMSO to a volume of RNA in BPE buﬀer
(6mM Na2HPO4, 2mM Na2H2PO4, 1mM EDTA, pH
7.1). The mixture was allowed to equilibrate for at least
20min at 48C to ensure complete association. The drug
stock was prepared so that upon reaching the desired con-
centration of drug, the amount of DMSO in the sample
was no >1% of the total volume. For absorption studies, a
constant concentration of drug (7mM) was titrated with
increasing amounts of RNA (0.5–20mM) and the absor-
bance was measured over the range of 400–600nm on a
Cary 50 Bio UV-vis spectrophotometer. Melting studies
were performed over a temperature range of 25–908C,
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Figure 1. (a) Human ferritin H-chain IRE 5 UTR, (b) human ferritin L-chain IRE 5 UTR, (c) anthracyclines investigated in this report, X=OH,
doxorubicin; X=H, daunomycin.
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every half degree. In order to favor hairpin formation and
avoid self-association, constructs were heated at 998C for
1min, then slowly cooled (18C/min) to 108C prior to being
melted from 258Ct o9 0 8C (33). For melting experiments,
absorbance was measured at 260nm, the temperature was
controlled with aQuantum Northwest TC 125 temperature
control unit, drug concentration varied between 5 and
20mM, and the concentration of RNA was held constant
at 2.5mM. The Tm was taken as the midpoint of the melting
transition as determined by the maxima of ﬁrst derivative
plots. An example of the ﬁrst derivative plots for ferritin
H-chain IRE RNA in the absence and presence of both
DOX and DAU can be found in the Supplementary
Material (Supplementary Figure S1). All Tms were repro-
ducible to within 18C. Repeated recording of heating and
cooling proﬁles indicates that no hysteresis occurs in the
absence or presence of ligand.
Fluorescence quenching experiments
Quenching of the drug’s natural ﬂuorescence upon
binding to RNA was monitored via titrations of a con-
stant concentration of drug (7mM) with RNA of increas-
ing concentration (0.1–20mM). Quenching experiments
were performed in a 96-well black microplate follow-
ing the protocol described by Hergenrother et al. (2).
Fluorescence emission at 556nm was recorded on a
Molecular Devices SpectraMAX Gemini microplate
reader after excitation at 480nm and 485nm for DOX
and DAU respectively. All experiments were repeated
at least four times. The data collected in the ﬂuores-
cence quenching titrations was ﬁt to a second-order
decay curve utilizing TableCurve 2D v5.01, equation
8107 (2):
y ¼
a   b
b þ x
Where b is the apparent dissociation constant, x is the
RNA concentration and a is the asymptotic limit.
Fluorescence quenching plots and curve ﬁts are avail-
able in the Supplementary Material.
A stock solution of 4M NaCl in BPE buﬀer was diluted
with BPE to achieve the various salt concentrations listed
in the paper (34).
RNase T1footprinting
The protocol for drug–RNA footprinting was adapted
from previously reported methods (35). RNA constructs
were 50-end-labeled with g-
32P ATP (PerkinElmer,
Waltham, MA) utilizing T4 polynucleotide kinase
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol. Labeled RNA (1.25mM), unlabeled
RNA (11.5mM) and drug (1–20mM) were combined in a
ﬁnal volume of 9ml of footprinting buﬀer (11mM Tris–
HCl, pH 7.0) and were allowed to equilibrate for 30min at
258C. The equivalent of 1U of RNase T1 enzyme (USB)
was added and allowed to proceed for 10min at 258C. The
reaction was quenched by the addition of 5ml of urea
loading buﬀer (8M urea, 20mM EDTA and 2mM Tris,
pH 7.5). Samples were then heated at 958C for 5min, and
11ml of each sample was run on a 12% denaturing acry-
lamide gel for 90min at 290V. The gel was then dried,
exposed to an IP plate (Fuji Film) and was visualized on
a Fuji Film FLA-3000 IP plate scanner. Quantiﬁcation of
band intensity was performed with the Fuji Film program
Multi Gauge version 3.0 utilizing proﬁle quantiﬁcation in
the direction of migration and a polygonal baseline for
background compensation.
RESULTS
UV melting andabsorbance experiments
The magnitude of ligand-induced change in nucleic acid
Tm [Tm=Tm(RNA+ligand)  Tm(RNA)] is an indica-
tion of the aﬃnity of the ligand for the nucleic acid target.
Hence, we performed UV melting experiments to obtain
the ﬁrst indication of a direct association between the
drugs and the IRE RNAs.
The UV melting curves of both ferritin H-chain and
L-chain IREs (Figure 2) display bi-phasic melting proﬁles
in the absence and presence of drug. The higher tempera-
ture transition (Tm=618C) is a minor transition and was
found to remain constant under all conditions. The lower
temperature transition revealed a concentration-depen-
dent increase in Tm in the presence of DOX and DAU.
The observed Tm for all construct and drug combina-
tions are presented in Table 1. It was found that the addi-
tion of drug to the IRE RNAs caused an increase in Tm
not only in a concentration-dependent manner but also in
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Figure 2. Overlay of the melting proﬁles of (a) ferritin H-chain mRNA and (b) ferritin L-chain mRNA in the absence (solid) and presence (dashed)
of 20mM DOX.
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a more substantial shift than DAU (Table 1, Supplemen-
tary Figure S1). It was also observed that the slight
changes in sequence and structure of the constructs led
to a graded degree of Tm shift in response to the presence
of drug. In the presence of 20 mM DOX, both the ferritin
heavy and light IREs produced a Tm of around 108C
(Table 1). Comparatively, the HIV-1 TAR RNA construct
(6,36), which is also a hairpin-loop structure that has been
shown to interact with small molecules, produced a max-
imum shift of 58C under the same conditions (data not
shown).
Guided by the results from the RNase footprinting
experiments on wild-type IREs (see details below), muta-
tions were made to the native H-chain IRE that altered
or removed certain structural features associated with
drug binding and recognition (37,38). We constructed
four point mutants designated U6C-IRE, C8A-IRE,
U10C-IRE and G23I-IRE (I=inosine) with mutations
at nucleotide positions 6, 8, 10 and 23, respectively;
and one double mutant designated U6C-U10C-IRE, bear-
ing double mutations that replaced the two UG pairs
with CG pairs. These mutations were predicted by
RNAstructure to preserve the IRE secondary structure.
The diﬀerence in Tm between these mutants and the
wild-type indicated the importance of both UG wobble
base pairs found in the ferritin IRE. The observed Tm
for the double mutant, U6C-U10C-IRE, which replaces
both UG wobble base pairs, was 5.58C and 1.58Ci n
the presence of 20mM DOX and DAU, respectively.
For the G23I-IRE mutant, the magnitudes of the
observed Tm are slightly higher than that of the wild-
type for both DOX and DAU at all concentration
studied (see Supplementary Material for melting curves).
Interestingly, U6C-IRE and U10C-IRE, mutants in which
one of the UG pairs is replaced with a CG, have identical
ligand-dependent Tm. However, their observed Tm is
about 38C less than that observed with the wild-type RNA
in the presence of 20 mM DOX.
Figure 3a shows the changes that occur in the absorp-
tion spectrum of DOX in the visible region during the
titration of a ﬁxed concentration of DOX with increasing
concentrations of the wild-type H-chain IRE. The result-
ing absorbance proﬁle of DOX yielded two distinct absor-
bance maxima at  472nm and 499nm and a marked
bathochromic shift was observed for both peaks resulting
in a   of 5nm and 10nm, respectively. Additionally, a
hypochromism of 33.7% for the ﬁrst maxima and 24.4%
for the second was observed.
Fluorescence quenching
The natural ﬂuorescence of DOX and DAU upon excita-
tion was monitored as they were titrated with increasing
amounts of RNA. The ﬂuorescence spectra show a
quenching of DOX ﬂuorescence signal upon titration
with IRE RNA (Figure 3b). The decay curves of the ﬂuo-
rescent signal were ﬁtted, and apparent Kds were calcu-
lated. It is important to note that this apparent Kd is a
total dissociation constant, and does not diﬀerentiate
between the contribution of direct drug binding (e.g. inter-
calation) and the contribution of electrostatic interaction
due to the charged nature of the anthracycline molecule.
The apparent Kds and associated standard errors of RNA
constructs are presented in Table 2.
Fluorescence quenching data at 25, 28, 30 and 358C was
used to perform a Stern–Volmer analysis (34,39,40) of
ferritin H-chain IRE RNA quenching DOX according
to the equation:
I0/I=1+KSV [Q]
Where I0 and I are the ﬂuorescence intensities in the
absence and presence of RNA, respectively, [Q] is the con-
centration of quencher (RNA) and KSV is the dynamic
quenching constant related to the bimolecular collision
process. For the quenching experiment at 25
8C, this ana-
lysis revealed a linear relationship between I0/I and [Q]
(Figure 3c). The linearity of the Stern–Volmer plot indi-
cates that the mode of quenching is either collisional or
static. Collisional and static quenching can be distin-
guished by their diﬀerent dependencies on temperature.
An increase in temperature leads to an increase in the
diﬀusion constant of the quencher and will result in an
increase in collisional quenching. In contrast, an increase
in temperature will lead to a decrease in the binding con-
stant of quencher for ﬂuorophore and will result in a
decrease in quenching for a static quencher (40). To iden-
tify the quenching mechanism, we repeated the quenching
experiments at 25, 28, 30 and 358C. Stern–Volmer analysis
of the resulting data revealed linear relationships between
I0/I and [Q] and also showed that the KSV is inversely
correlated with temperature (Figure 3c). Based on this
result, it could be concluded that the probable quenching
mechanism of the DOX-H-chain IRE–RNA complex is
initiated by static quenching (39,40).
To determine the drug/RNA stoichiometry, we use the
ﬂuorescence quenching data to construct Job plots
(Figure 4) (41,42). The x-axis of the Job plot, labeled as
the mole fraction, is the ratio of the concentration of RNA
to the total concentration of RNA and drug, or: Mole
Table 1. The average Tms observed for all drug and IRE combinations
Ligand H-chain L-chain G23I-IRE U10C-IRE U6C-IRE C8A-IRE U6C-U10C-IRE
5mM DOX 2.5 2.7 4.7 3.7 2.6 3.9 1.0
20mM DOX 9.9 10.1 10.3 6.8 6.5 7.9 5.5
5mM DAU 0.5 3.5 3.8 1.7 1.5 2.9 0.5
20mM DAU 5.7 6.5 7.3 4.7 4.0 5.9 1.5
Average Tm values can be found in the Supplementary Material (Table S1).
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of [RNA] and [drug] was held constant at 7mM. The inter-
section of the two linear portions of the Job plot yield the
mole ratio corresponding to the approximate binding stoi-
chiometry between drug and RNA. This analysis revealed
a mole fraction corresponding to  3.0 molecules of drug
associating with each molecule of the H-chain IRE RNA.
To further conﬁrm the participation of the UG pairs in
anthracycline binding, we also constructed Job plots using
the ﬂuorescence quenching data of the mutants IREs. We
obtained a binding stoichiometry of  2.0 molecules of
drug associating with each molecule of either U10C or
the double mutant U6C, U10C (See Supplementary
Figure S3).
Binding energy
In an eﬀort to partition the binding free energies of
anthracyclines with the IRE RNAs into their nonelectro-
static and polyelectrolyte contributions, ﬂuorescence
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Figure 3. (a) Absorbance proﬁles of 7mM DOX in the presence of (from 1 to 6) 0, 0.5, 1.0, 2.5, 7 and 20mM ferritin H-chain IRE RNA.
(b) Fluorescence proﬁles of the titration of 7mM DOX with (from 1 to 8) 0, 1, 1.5, 2.5, 5, 7, 10 and 15mM ferritin H-chain IRE RNA.
(c) Stern–Volmer plot of 7mM DOX with ferritin H-chain IRE RNA at the indicated temperatures. (d) Stern–Volmer plot of 7mM DOX with
ferritin H-chain IRE RNA in BPE of the following Na
+ concentrations: 16mM (ﬁlled diamond), 46mM (open diamond), 116mM (ﬁlled square),
216mM (open square) and 516mM (ﬁlled circle). Each Stern–Volmer plot was obtained from an average of at least four independent experiments.
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Figure 4. Job plot of the ﬂuorescence decay of DOX (20 mM) being
titrated with ferritin H-chain IRE RNA. The sum of [RNA] and
[drug] was held constant at 7mM in each experiment {Mole
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Table 2. Apparent Kds and standard errors of association of DOX with wild-type and mutant IREs
H-chain L-chain G23I-IRE U10C-IRE U6C-U10C-IRE
Apparent Kd (nM) 904 837 903 991 1100
Fit Std Error (nM)  30.9  32.7  22.0  13.2  38.5
Nucleic Acids Research, 2008, Vol. 36, No. 21 6829quenching was monitored over a range of Na
+ concen-
trations, and a Stern–Volmer plot for each was plotted
(Figure 3d) (25). The quenching constant (Ksv) was
determined for each curve and was then used to cal-
culate the standard Gibbs free energy (G8) using the
equation:
G8= RT ln Ksv
Where R is the gas constant (1.987cal/K/mol) and T is the
temperature in Kelvin. The quenching constants estimated
at 25, 28, 30 and 35
8C are 6.2 10
5M
 1, 5.0 10
5M
 1,
4.6 10
5M
 1 and 3.8 10
5M
 1, respectively. A subse-
quent plot of log Ksv versus log [Na
+] yielded the salt
dependence of the binding constant deﬁned by the slope
(SK) of such plots. The SK value ( 0.83 for DOX and
ferritin H-chain IRE) was used in the following equation
to determine the polyelectrolyte contribution (Gpe)a ta
given salt concentration (25,43):
Gpe=(SK) RT ln [Na
+]
To determine the nonelectrostatic contribution to binding
energy, the thermodynamic free energy change (Gt) was
calculated according to the equation (25):
Gt=G8 Gpe
The values obtained for the binding of DOX to H-chain
IRE RNA (BPE buﬀer, 16mM Na
+,2 5 8C) are as
follows: G8= 7.7kcalmol
 1, Gpe= 2.0kcalmol
 1
and Gt= 5.7kcalmol
 1. The error associated with
these values is estimated to be 0.1kcalmol
 1 (25).
A comparable value of Gpe has been reported for the
binding of DOX to DNA under similar conditions (25).
Drug–RNA footprinting
RNase footprinting was performed in order to probe the
binding site(s) of DOX and DAU on the RNA constructs.
Of the several RNases investigated, RNase T1 was found
to provide the cleanest and most useful cleavage pattern.
RNase T1 cleaves single-stranded RNA at the 30-end of
guanylic residues and, as expected, it caused strong clea-
vage of the RNA at G7, G16 and G18, all residues pre-
dicted by RNAstructure to be within the single-stranded
region of the IRE secondary structure (Figure 5a). The
most striking observation from this autoradiograph is
that T1 cleavage at G22/G23 and G26/27, the nucleotide
positions corresponding to the two UG sites, displayed a
drug concentration-dependent increase in band intensity
(Figure 5a). While G16 also showed some variation in
band intensity, comparison of the quantitated G16 and
G23 band intensities, after the footprinting of the
H-chain IRE with DOX, revealed that G23 displayed a
consistent and marked concentration-dependent increase
in cleavage intensity compared to G16 (Figure 5b).
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Figure 5. (a) Autoradiograph of RNase T1 footprinting of g-
32P5 0-end-labeled ferritin H-chain IRE RNA (lanes 1–8) and H-chain U10C mutant
(lanes 9–16). Lane: (1) H-chain RNA only; (2–8) RNA, RNase T1 and 0, 1, 2.5, 5, 10, 15, 20 mM DOX, (9) H-chain U10C mutant RNA only; (10–
16) RNA, RNaseT1 and 0, 1, 2.5, 5, 10, 15, 20 mM DOX. The G 23 band, indicated by the arrow, is absent for the mutant. (b) Quantitations of the
G16 and G23 bands intensities of ferritin H-chain IRE RNA after RNase T1 footprinting in the presence of DOX. DOX concentration for each
band is indicated in the legend.
6830 Nucleic Acids Research, 2008, Vol. 36, No. 21We then used RNase T1 footprinting to follow the
eﬀects of the aforementioned mutations on cleavage at
G23, the guanylic residue of one of the UG pairs
(U10G23) that showed T1 cleavage enhancement in the
presence of DOX. We chose to monitor G23 because it
is the better resolved of the two G residues on the auto-
radiograph (Figure 5a). In a manner similar to the wild-
type H-chain IRE, the footprinting of the G23I mutant
with DOX displayed a drug concentration dependent
increase in band intensity at G23 (data not shown).
Conversely, the footprint of the U10C-IRE, the mutant
which replaced the top UG pair, lacks the band corre-
sponding to G23 when compared to that of the wild-
type H-chain IRE (Figure 5a). Validation of the cleavage
band designations can be found in the supplementary
material (Supplementary Figure S4).
DISCUSSION
Anthracycline–DNA interactions are among the best
characterized in the literature (24–32). Despite their
chemical similarity to DNA and direct role in gene expres-
sion, little is known about the extent to which RNA inter-
actions with anthracyclines contribute to anthracyclines’
biological activities. In this article, we demonstrate that
DOX and DAU directly interact with the IREs hairpins
(Figure 1a and b) located in the 50-UTR of ferritin H- and
L-chains mRNAs. DOX and DAU caused a concentra-
tion-dependent shift in the melting proﬁles of the H- and
L-chains IREs (Figure 2 and Supplementary Figure S1).
In most cases, we observed higher Tms for DOX com-
pared to DAU for all IRE RNAs studied under the same
conditions (Table 1). Since the magnitude of Tm is an
indication of the aﬃnity of a probe molecule for a nucleic
acid target (44), the noted diﬀerences in the values of
Tms suggest that DOX binds tighter to these RNAs
compared to DAU. The lower Tms observed for DAU
(Table 1, bottom half) is consistent with the literature
report indicating that DAU binds to DNA between 1.5-
to 4-fold less strongly than DOX (31). Furthermore, the
only structural diﬀerence between the two drugs is the
presence of a primary OH-group at C14 of DOX
(Figure 1c); it is therefore possible that the OH-group at
C14 is playing a role in the binding of anthracyclines to
the RNAs, perhaps in a similar manner to its involvement
in DNA binding and recognition (45).
The drug induced changes in the melting proﬁles of the
mutant IREs gave further evidence for the base sequence
preference of the interactions between the anthracyclines
and the IRE RNAs. While the asymmetric bulge in the
H-chain IRE is somewhat tolerant of a base change, the
replacement of either or both of the UG wobble pairs
ﬂanking the asymmetric bulge with a CG signiﬁcantly
impaired DOX and DAU binding (Table 1). These results
point to the requirement of the UG base pairs in facilitat-
ing the binding of DOX and DAU to the IRE RNAs.
However, the UG base pair recognition by anthracyclines
may be RNA sequence dependent. Preliminary evidence
to that eﬀect was seen in the melting proﬁle of a C22U
mutant TAR RNA. Relative to the wild-type TAR RNA,
we observed almost no change in TM of the C22U
mutant in the presence of 20mM DOX. This result may
suggest that the microenvironment of the UG pairs within
the RNA sequence may play important role in anthracy-
cline recognition (see Supplementary Figure S2, for
the melting proﬁles of wild-type and C22U mutant
TAR RNA).
The ability of IRE RNAs to alter the spectral charac-
teristics of anthracyclines gives further indication of an
interaction of drug and RNA (Figure 3a and b). We
observed a quenching of the natural ﬂuorescence of
DOX and DAU with increasing RNA concentration
(Figure 3b). The quenching of DOX ﬂuorescence by
DNA has been ascribed to its intercalation into DNA
(27,46). Thus, we attribute the extensive ﬂuorescence
quenching (>90% at a 2:1 ratio of DOX to H-chain
IRE RNA) to the intercalation of one or more anthracy-
cline molecules per RNA molecule (Figure 3b). A similar
interpretation has recently been proposed to explain DOX
ﬂuorescence quenching by a SELEX generated DOX
RNA aptamer (5). Additionally, the titration of a ﬁxed
concentration of DOX with increasing concentrations of
the wild-type H-chain IRE results in a hyprochromic eﬀect
accompanied by a shift of the absorption maximum ( max)
to a longer wavelength (bathochromic shift). The observed
maximal absorbance decrease is  33.7% (Figure 3a).
These results are indicative of changes in the drug’s envi-
ronment and a perturbation of the DOX chromophore
system upon binding to the IRE RNA, consistent with
intercalative binding of DOX within the IRE RNA.
Furthermore, the apparent Kd (Tables 2) extracted from
the ﬂuorescence quenching data give an indirect clue
about the aﬃnity of DOX for the IREs. Although we
did not have suﬃcient information to diﬀerentiate
between the contribution of direct drug binding and that
of electrostatic interaction for all IRE constructs, the mag-
nitudes of the apparent Kd’s suggest strong association of
the drug with the IREs.
We performed RNase footprinting experiments to gain
more insight into the binding site(s) of DOX and DAU on
the ferritin H-chain IRE and a series of mutant RNAs
(47,48). Results from the drug–RNA footprinting experi-
ments show that the T1 cleavage at two sites, G22/G23
and G26/27, is enhanced upon addition of DOX
(Figure 5a). Chaires et al. (48) have attributed an analo-
gous enhancement in nuclease cleavage of DNA, in the
presence of DAU, to the perturbation of DNA structure
in the immediate vicinity of a DAU intercalation site. If
this explanation holds for RNA, our results suggest the
existence of at least two main drug binding sites at or near
the two UG wobble base pairs of the ferritin H-chain IRE
(Figure 5). Interaction of anthracycline molecules at both
of these proposed binding sites would not violate the near-
est neighbor exclusion rule when applied to anthracycline–
nucleic acid binding (27).
Wobble pairs, especially GU or UG, are ubiquitous
building blocks of higher order RNA structures.
Compared to regular Watson–Crick base pairs, wobble
pairs diﬀer in both the array of functional groups dis-
played in the helical grooves and the orientation of
the bases with respect to the phosphodiester backbone.
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ening of the helix and local distortions which signiﬁcantly
increase the electronegative environment at or near the
mismatch pair (49,50). The two UG pairs in the ferritin
H-chain IRE could each provide an electronegative envi-
ronment for nestling the electropositive DOX. In fact, the
wobble pair has been shown to be a commonly conserved
ligand binding site (49). To further probe this observation,
we extensively studied the eﬀects of mutation of the two
UG pairs and bulge C on the binding aﬃnity of DOX for
the IRE RNA. Results from these experiments show that
all mutations that preserved the U10-G23 wobble dis-
played essentially the same cleavage pattern as in the
wild-type RNA. This suggests that these mutants are
able to induce the structural changes necessary for DOX
binding within the vicinity of U10-G23. More impor-
tantly, however, the G23I mutant sheds light on the
speciﬁcs of the UG pair recognition by DOX. The G23I
mutation results in the deletion of the guanosine N2
exocyclic amine, a very distinct functional group displayed
in the minor groove of a wobble that often serves as a
speciﬁc receptor recognition signal. The fact that the
G23I-IRE mutant also displayed increase in Tm and
enhancement of T1 cleavage at G23 in the presence of
DOX suggest the G23 amine may not be essential for
DOX recognition by the ferritin H-chain IRE (see
Supplementary Material for the UV melting proﬁles for
construct G23I, Supplementary Figure S5). An alternative
mechanism of ligand recognition of a wobble pair is
through its unique conformational features. This may
well be exploited by DOX in its interaction with the
H-chain IRE. This inference is supported by two key
observations. First, the magnitudes of the observed
TMs for the G23I-IRE mutant are slightly higher than
that of the wild-type in the presence of either DOX or
DAU at all concentration studied (Table 1). These data
suggest that the substitution of G23 for I may have
resulted in slightly increased RNA ligand-binding aﬃnity.
Previous literature observation indicates that an IU base
pair is slightly less stable than a GU pair (50). The subtle
duplex instability as a result of the G23I mutation may
enhance the structural changes essential for ligand bind-
ing, thereby resulting in increased interaction of ligand
with the RNA. Second, the G23 band in the U10C, a
mutant IRE in which the G23-U10 is substituted by a
GC base pair, is protected from T1 cleavage (Figure 5).
Based on the increased GC content, one will expect this
mutation to increase the binding aﬃnity of DOX for the 5-
base paired segment of the IRE. The protection of G23
from T1 digestion may be due to diminished or lack of
DOX binding, thereby preventing the necessary confor-
mational changes that expose G23 to T1. Alternatively,
it may also be that DOX binding persists but is not accom-
panied by a conformational change that is sensitive to T1
cleavage.
The Stern–Volmer analysis of the drug ﬂuorescence
quenching data supports a static mechanism for the
quenching of the DOX ﬂuorescence by the H-chain IRE
RNA (Figure 3c and d). The static quenching could occur
through the formation of a complex, stabilized mainly by
hydrophobic interactions, between DOX (ﬂuorophore)
and RNA (quencher) (39,40). This complex could result
from the intercalation of DOX into the IRE bases as sug-
gested by the aforementioned evidence. In addition, the
Stern–Volmer analysis allows an estimation of the equili-
brium constant for the formation of the DOX-H-chain
IRE RNA complex. Applying the polyelectrolyte theory
(25,43), these equilibrium constants enable the dissection
of the RNA binding free energies of anthracyclines into
their nonelectrostatic and polyelectrolyte contributions.
The calculated value of Gpe is very similar to that
reported for the binding of DOX to DNA under similar
conditions (25). This result suggests a similar polyelectro-
lyte contribution to the overall G of binding of DOX to
DNA and RNA. A Job plot of the ﬂuorescence quenching
of DOX with wildtype IRE RNA gives a drug to RNA
binding ratio of  3.0:1 (Figure 4). A similar plot of the
U10C IRE, a mutant in which one of the proposed bind-
ing sites has been replaced with a GC pair, resulted in a
drug to RNA stoichiometry of 2.0:1 (Supplementary
Figure S3). This result is consistent with our original infer-
ence on the participation of U10-G23 wobble pair in DOX
binding to the IRE. However, the drug to RNA stoichio-
metry remained 2.0:1 when both UG pairs are replaced
(Supplementary Figure S3). The lack of further change in
the drug to RNA ratio upon the replacement of the pro-
posed second DOX binding site may be due to the fact
that the second mutation did not completely abolish DOX
binding. Although footprinting only identiﬁed the two
UG sites as possible binding sites, the nonelectrostatic
binding energy, Gt, was found to account for only
74% of the total observed change in G upon DOX bind-
ing to IRE RNA. Taken together, these data suggest that
in addition to the intercalation of two anthracycline mole-
cules at the UG sites, there is at least one additional site of
interaction, most likely electrostatic in nature, on the
IRE RNA.
The crystal structure of IRP1 bound to frog ferritin IRE
has recently been solved (51). The structure reveals almost
twice the number of speciﬁc interactions found in most
protein–RNA associations. Despite the level of interac-
tion, single mutations to just a few of the residues involved
have been shown to greatly diminish the IRE/IRP inter-
action (37,52,53). This high degree of structural and
sequence selectivity reveals the seemingly robust interac-
tion to be in fact very sensitive to minute disturbances.
The binding of anthracycline molecules to the IRE struc-
ture could cause changes to the tertiary structure of the
IRE RNA that could diminish the aﬃnity of IRP for the
IRE. This may cause an aberration in the intracellular
regulation of the translation of mRNAs harboring these
IREs. Supporting this hypothesis is a recent observation
from the Thorp group on up-regulation of the cellular
expression of ferritin upon exposure to yohimbine, a
small molecule that binds to the ferritin IRE (3).
The biochemical evidence presented in this study sug-
gests that anthracyclines form strong and speciﬁc interac-
tions with IRE RNAs. Furthermore, it sheds light on
some of the structural requirements for this interaction.
Although anthracyclines such as DOX and DAU have
been reported to show a requirement for GC sequences
in DNA binding (48,54), we have presented evidence that
6832 Nucleic Acids Research, 2008, Vol. 36, No. 21the binding of anthracyclines to ferritin IRE RNA demon-
strates a strong preference for UG pairs. The prevalence of
wobble base pairs in higher order RNA structures (49)
suggests that this non-canonical pair, when structurally
available, could serve as a ubiquitous recognition site for
the binding of anthracyclines to other RNAs as well.
Further studies are necessary to better understand the
possible biological signiﬁcance of the anthracycline-IRE
interaction. Part of our ongoing eﬀort is to probe the
eﬀects of DOX and DAU on IRE-IRP complex formation
both in vitro and in vivo.
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Supplementary Data are available at the NAR Online.
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